
## Sarita Rani Jaiswal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7175535/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Improved Outcome of Refractory/Relapsed Acute Myeloid Leukemia after Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation with Myeloablative Conditioning and Early Prophylactic Granulocyte Colony-Stimulating Factor–Mobilized Donor Lymphocyte Infusions. Biology of Blood and Marrow Transplantation, 2016, 22, 1867-1873.	2.0	62
2	Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-, Busulfan-, and Melphalan-Based Conditioning. Biology of Blood and Marrow Transplantation, 2016, 22, 499-504.	2.0	60
3	CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: A pilot study, Cytotherapy, 2017, 19, 531-542.	0.3	50
4	T cell costimulation blockade promotes transplantation tolerance in combination with sirolimus and post-transplantation cyclophosphamide for haploidentical transplantation in children with severe aplastic anemia. Transplant Immunology, 2017, 43-44, 54-59.	0.6	42
5	Haploidentical transplantation in children with unmanipulated peripheral blood stem cell graft: The need to look beyond postâ€ŧransplantation cyclophosphamide in younger children. Pediatric Transplantation, 2016, 20, 675-682.	0.5	26
6	Hemophagocytic syndrome following haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide. International Journal of Hematology, 2016, 103, 234-242.	0.7	23
7	Alterations in NKG2A and NKG2C Subsets of Natural Killer Cells Following Epstein–Barr Virus Reactivation in CTLA4lg-based Haploidentical Transplantation Is Associated With Increased Chronic Graft-Versus-Host Disease. Transplantation, 2020, 104, e23-e30.	0.5	22
8	CTLA4Ig Primed Donor Lymphocyte Infusion: A Novel Approach to Immunotherapy after Haploidentical Transplantation for Advanced Leukemia. Biology of Blood and Marrow Transplantation, 2019, 25, 673-682.	2.0	21
9	T cell costimulation blockade for hyperacute steroid refractory graft versus-host disease in children undergoing haploidentical transplantation. Transplant Immunology, 2016, 39, 46-51.	0.6	17
10	Higher CD45RA+ Regulatory T Cells in the Graft Improves Outcome in Younger Patients Undergoing T Cell–Replete Haploidentical Transplantation: Where Donor Age Matters. Biology of Blood and Marrow Transplantation, 2018, 24, 2025-2033.	2.0	17
11	CTLA4lg in an Extended Schedule along with Sirolimus Improves Outcome with a Distinct Pattern of Immune Reconstitution Following Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation for Hemoglobinopathies. Biology of Blood and Marrow Transplantation, 2020, 26, 1469-1476	2.0	14
12	1469-1476 Impact of Single-Dose Plerixafor as an Adjunct to Granulocyte Colony-Stimulating Factor–Based Peripheral Blood Stem Cell Mobilization on the Graft Composition and Outcome for T Cell–Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: A Comparative Study. Biology of Blood and Marrow Transplantation, 2018, 24,	2.0	13
13	542-548. Focusing On A Unique Innate Memory Cell Population Of Natural Killer Cells In The Fight Against COVID-19: Harnessing The Ubiquity Of Cytomegalovirus Exposure. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020047.	0.5	12
14	Impact of extended infusional mesna prophylaxis on the incidence of BK viruria and hemorrhagic cystitis following post-transplantation cyclophosphamide and CTLA4Ig-based haploidentical transplantation. Annals of Hematology, 2020, 99, 839-845.	0.8	12
15	Early and Sustained Expansion of Adaptive Natural Killer Cells Following Haploidentical Transplantation and CTLA4lg-Primed Donor Lymphocyte Infusions Dissociate Graft-versus-Leukemia and Graft-versus-Host Effects. Transplantation and Cellular Therapy, 2021, 27, 144-151.	0.6	12
16	Impact of adaptive natural killer cells, KLRC2 genotype and cytomegalovirus reactivation on late mortality in patients with severe COVIDâ€19 lung disease. Clinical and Translational Immunology, 2022, 11, e1359.	1.7	11
17	Haploidentical Transplantation in Children with Acute Leukemia: The Unresolved Issues. Advances in Hematology, 2016, 2016, 1-11.	0.6	10
18	CTLA4Ig-based reduced intensity conditioning and donor lymphocyte infusions for haploidentical transplantation in refractory aggressive B-cell lymphoma relapsing after an autograft: Early results from a pilot study. Experimental Hematology, 2019, 77, 26-35.e1.	0.2	9

SARITA RANI JAISWAL

#	Article	IF	CITATIONS
19	Natural killer cell-based immunotherapy with CTLA4Ig-primed donor lymphocytes following haploidentical transplantation. Immunotherapy, 2019, 11, 1221-1230.	1.0	9
20	CTLA4Ig-based T-cell costimulation blockade is associated with reduction of adenovirus viremia following post-transplantation cyclophosphamide-based haploidentical transplantation. Bone Marrow Transplantation, 2020, 55, 649-652.	1.3	9
21	Impact of Preemptive Granulocyte Infusions During Febrile Neutropenia in Patients Colonized with Carbapenem-Resistant Gram-Negative Bacteria Undergoing Haploidentical Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1621-1628.	2.0	8
22	CTLA4Ig-primed donor lymphocyte infusions following haploidentical transplantation improve outcome with a distinct pattern of early immune reconstitution as compared to conventional donor lymphocyte infusions in advanced hematological malignancies. Bone Marrow Transplantation, 2021, 56, 185-194.	1.3	7
23	Paternal bone marrow infusion as salvage therapy for severe GVHD following maternal haploidentical transplantation resulting in biparental chimerism. International Journal of Hematology, 2013, 98, 504-508.	0.7	6
24	Targeting CD28-CD86 Pathway for Refractory Myeloma Through CTLA4Ig-Based Reduced-Intensity Conditioning and Donor Lymphocyte Infusions After Haploidentical Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e430-e435.	0.2	6
25	Early Expansion of CD56dim NKG2Alow with Late Surge and Persistence of CD56dimNKG2AnegNKG2Cbright NK Cells Attenuate Cytomegalovirus (CMV) Replication and Recurrence As Well As Leukemia Relapse Following Haploidentical HSCT with T Cell Co-Stimulation Blockade and Ptcv. Biology of Blood and Marrow Transplantation. 2019. 25. S328.	2.0	6
26	Safety and efficacy of Sofosbuvir and Velpatasvir in children with active hepatitis C virus infection undergoing haploidentical transplantation. Transplant Infectious Disease, 2021, 23, e13490.	0.7	5
27	Impact of an Immune Modulator Mycobacterium-w on Adaptive Natural Killer Cells and Protection Against COVID-19. Frontiers in Immunology, 2022, 13, .	2.2	5
28	Prophylactic oseltamivir during major seasonal influenza H1N1 outbreak might reduce both H1N1 and associated pulmonary aspergillosis in children undergoing haploidentical transplantation. Transplant Infectious Disease, 2020, 22, e13309.	0.7	4
29	Contrasting Patterns of Alloreactivity Amongst Malignant and Nonmalignant Diseases Receiving Haploidentical PBSC GRAFT and Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2013, 19, S346.	2.0	3
30	Allogeneic Hematopoietic Stem Cell Transplantation for Myeloma: Time for an Obituary or Not Just Yet!. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 416-422.	0.3	3
31	Effect of dose and schedule of L-asparaginase administration on early minimal residual disease in acute lymphoblastic leukemia. Indian Journal of Medical and Paediatric Oncology, 2019, 40, 496.	0.1	2
32	Developing a Haploidentical Transplant Program: An Indian Experience. Biology of Blood and Marrow Transplantation, 2015, 21, S66.	2.0	1
33	Pretransplant Sirolimus Improves Outcome of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Patients with Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2015, 21, S159.	2.0	1
34	Early Donor Lymphocyte Infusion and NK Ligand Mismatched Donor Might Improve the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Following Posttransplantation Cyclophosphamide-Based Haploidentical PBSC Transplantation with Myeloablative Conditioning. Biology of Blood and Marrow Transplantation, 2016, 22, S81-S82.	2.0	1
35	CD45RA+ Regulatory T Cells (Tregs) in the Graft is Inversely Related to Donor Age and Impacts Early Alloreactivity and Survival in Younger Patients Undergoing Haploidentical PBSC Transplantation with Post-Transplantation Cyclophosphamide (PTCy). Biology of Blood and Marrow Transplantation, 2018, 24, S88-S89.	2.0	1
36	Rotavirus infection following postâ€transplantation cyclophosphamide based haploidentical hematopoietic cell transplantation in children is associated with hemophagocytic syndrome and high mortality. Transplant Infectious Disease, 2019, 21, e13136.	0.7	1

SARITA RANI JAISWAL

#	Article	IF	CITATIONS
37	Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Primary Refractory Acute Myeloid Leukemia. Blood, 2015, 126, 4411-4411.	0.6	1
38	Gut Colonization with Carbapenem Resistant Enterobactriaceae (CRE) Adversely Impacts the Outcome in Patients with Hematological Malignancies: Results of a Prospective Surveillance Study. Blood, 2016, 128, 2402-2402.	0.6	1
39	Haploidentical Transplantation with PBSC Graft in Children: The Need to Look Beyond Post-Transplantation Cyclophosphamide in Younger Children. Biology of Blood and Marrow Transplantation, 2016, 22, S250.	2.0	Ο
40	CD56 Enriched Donor Cell Infusion Following Post-Transplantation Cyclophosphamide and Cyclosporine Alone for Haploidentical PBSCT in Myeloid Malignancies Is Associated with Prompt Reconstitution of Mature NK Cells and Tregs with Reduced Incidence of aGVHD. Biology of Blood and Marrow Transplantation, 2017, 23, S82-S83.	2.0	0
41	A Comparative Analysis of Graft Composition and Outcome with the Use of Single Dose Plerixafor as an Adjunct to GCSF Based PBSC Mobilisation for T Replete Haploidentical PBSC Transplantation with Post Transplantation Cyclophosphamide : A Pilot Study. Biology of Blood and Marrow Transplantation. 2018. 24. S207-S208.	2.0	0
42	Long Term Maintenance of Hickman Catheter in Methicillin Resistant Staphylococcus Colonized Patients Undergoing Haploidentical HSCT: Results of a Prospective Study. Biology of Blood and Marrow Transplantation, 2019, 25, S434.	2.0	0
43	A Prospective Study on the Impact of Pre-Emptive Granulocyte Infusion (PGI) in Carbapenem-Resistant Gram Negative Bacilli (CRGNB) Colonized Patients Undergoing Haploidentical HSCT. Biology of Blood and Marrow Transplantation, 2019, 25, S74.	2.0	0
44	CTLA4Ig Limits Both Incidence and Severity of Early Cytokine Release Syndrome following Haploidentical Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, e86-e87.	2.0	0
45	Haploidentical Transplantation: Challenges and Solutions. Organ and Tissue Transplantation, 2021, , 223-263.	0.0	0
46	Sirolimus as long-term graft-versus-host-disease prophylaxis in haploidentical hematopoietic stem cell transplant recipients for non-malignant disorders is associated with high incidence of acneiform lesions. Indian Journal of Dermatology, 2015, 60, 588.	0.1	0
47	Haploidentical Transplantation: Challenges and Solutions. Organ and Tissue Transplantation, 2020, , 1-41.	0.0	0